48,460
edits
Difference between revisions of "Renal neoplasms with TSC/mTOR pathway mutations"
Jump to navigation
Jump to search
Renal neoplasms with TSC/mTOR pathway mutations (view source)
Revision as of 04:28, 20 March 2024
, 20 Marchno edit summary
m (Michael moved page Renal neoplasms with TSC/mTOR mutations to Renal neoplasms with TSC/mTOR pathway mutations: fix title) |
|||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Renal neoplasms with TSC/mTOR mutations''' is a diverse group of [[kidney tumours]]. | '''Renal neoplasms with TSC/mTOR pathway mutations''' is a diverse group of [[kidney tumours]].<ref>{{cite journal |authors=Kapur P, Brugarolas J, Trpkov K |title=Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting |journal=Cancers (Basel) |volume=15 |issue=16 |pages= |date=August 2023 |pmid=37627070 |pmc=10452688 |doi=10.3390/cancers15164043 |url=}}</ref> | ||
Kidney tumours with TSC/mTOR mutations: | Kidney tumours with TSC/mTOR mutations: | ||
*[[Renal cell carcinoma with fibromyomatous stroma]].<ref name=pmid37899532>{{cite journal |authors=Shah RB, Mehra R |title=Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up |journal=Adv Anat Pathol |volume=31 |issue=2 |pages=105–117 |date=March 2024 |pmid=37899532 |doi=10.1097/PAP.0000000000000419 |url=}}</ref> | |||
*[[Eosinophilic solid and cystic renal cell carcinoma]].<ref name=pmid35203531>{{cite journal |authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O |title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background |journal=Biomedicines |volume=10 |issue=2 |pages= |date=January 2022 |pmid=35203531 |pmc=8869370 |doi=10.3390/biomedicines10020322 |url=}}</ref> | *[[Eosinophilic solid and cystic renal cell carcinoma]].<ref name=pmid35203531>{{cite journal |authors=Pivovarcikova K, Alaghehbandan R, Vanecek T, Ohashi R, Pitra T, Hes O |title=TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background |journal=Biomedicines |volume=10 |issue=2 |pages= |date=January 2022 |pmid=35203531 |pmc=8869370 |doi=10.3390/biomedicines10020322 |url=}}</ref> | ||
*[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/> | *[[Eosinophilic vacuolated tumour]].<ref name=pmid35203531/> | ||
*[[Low-grade oncocytic tumour]].<ref name=pmid35203531/> | *[[Low-grade oncocytic tumour]].<ref name=pmid35203531/> | ||
Mnemonic: ''REEL''. | |||
==See also== | |||
*[[Everolimus]]. | |||
==References== | ==References== | ||